anti-ag-4-complement-fixing antibodies were detected in 40 % of dysplasia patients , 60 % of carcinoma-in-situ patients , 75 % of cacx patients , 65 % of cacx post-operative patients , 88 % of hsv-2 patients with active lesions , 10 % of hsv-1 patients with active lesions , 10 -- 20 % of normal patients and 20 % of patients with cancer , other than cacx .
C0006826
cancer
C0302592
cacx